# Safety and Efficacy of AGN208397 in the Treatment of Macular Edema Associated With Retinal Vein Occlusion (RVO)

> **NCT01027650** · PHASE1,PHASE2 · COMPLETED · sponsor: **Allergan** · enrollment: 121 (actual)

## Conditions studied

- Macular Edema
- Retinal Vein Occlusion

## Interventions

- **DRUG:** AGN208397 intravitreal injection
- **DRUG:** dexamethasone intravitreal implant

## Key facts

- **NCT ID:** NCT01027650
- **Lead sponsor:** Allergan
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-03
- **Primary completion:** 2012-04
- **Final completion:** 2013-02
- **Target enrollment:** 121 (ACTUAL)
- **Last updated:** 2014-04-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01027650

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01027650, "Safety and Efficacy of AGN208397 in the Treatment of Macular Edema Associated With Retinal Vein Occlusion (RVO)". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT01027650. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*